Adjuvant Imatinib Beyond 3 Years in High-Risk GIST: 5-Year Relapse-Free Survival Outcomes
Extending Imatinib beyond 3 years did not improve survival for high-risk GIST patients.
This retrospective cohort study evaluated adjuvant imatinib duration in 75 patients with high-risk GIST after radical surgery. Extending the…
A look at past data shows taking Imatinib longer than three years did not help high-risk GIST patients live longer or stay cancer-free.
In children with Ph+ ALL, TKI-based therapy reduced HSCT use while maintaining comparable outcomes versus Ph+ALL04.
Reduced transplant use showed similar outcomes in children with Philadelphia chromosome-positive leukemia
This single-arm Phase 2 trial evaluated chemotherapy with tyrosine kinase inhibitors (TKIs) guided by minimal residual disease in 41 eligibl…
Children with a specific leukemia type achieved similar survival rates without stem cell transplants, offering a less intensive treatment op…
Imatinib reduces TNF-α levels in CML patients; persistent levels correlate with poor response
Imatinib treatment reduces inflammatory marker in CML patients in small study
A prospective observational cohort of 40 chronic-phase CML patients in India found imatinib significantly reduced serum TNF-α levels from 25…
Dropping inflammation markers in CML patients on imatinib treatment may help doctors predict who will respond well to the drug.